Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Accumulated Depreciation (2023 - 2024)

Contineum Therapeutics has reported Accumulated Depreciation over the past 2 years, most recently at $1.7 million for Q4 2024.

  • Quarterly results put Accumulated Depreciation at $1.7 million for Q4 2024, up 16.25% from a year ago — trailing twelve months through Dec 2024 was $1.7 million (up 16.25% YoY), and the annual figure for FY2024 was $1.7 million, up 16.25%.
  • Accumulated Depreciation for Q4 2024 was $1.7 million at Contineum Therapeutics, up from $1.5 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation for CTNM hit a ceiling of $1.7 million in Q4 2024 and a floor of $1.5 million in Q4 2023.